|
|
||||||||||||||||||||||||||||||||||||||||||||||||||
By The Online Investor Staff, updated Mon., Apr. 12, 11:12 AM
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Secondary Stock Offerings| This Slide: #13 of 25 |
Slide #13. 9 Meters Biopharma, Inc. — Secondary Offering
Company:
9 Meters Biopharma, Inc. (NASDAQ:NMTR)
Date announced:
3/30/2021
Shares Offered:
30,000,000
Date of Pricing:
3/30/2021
Price Per Share:
$1.00
Secondary Offering Details:
9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that it has commenced a proposed underwritten public offering of shares of its common stock. In connection with this offering, 9 Meters Biopharma expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock to be sold in the offering. All of the shares in the proposed offering are to be sold by 9 Meters Biopharma. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 3/30- 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a price to the public of $1.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 4,500,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on April 5, 2021, subject to customary closing conditions.
9 Meters Biopharma a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. Co.'s pipeline includes drug candidates for celiac disease, nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis, Crohn's disease and ulcerative colitis (UC). Co.'s key program, INN-202 (larazotide acetate or larazotide) is entering Phase 3 registration trials for celiac disease. Co. is also developing larazotide for the treatment of NASH (INN-217), a smaller subset of liver disease stemming from the fatty liver disease. INN-108 is an oral small molecule therapeutic for UC. Co. owns the global rights to INN-329, a key formulation of secretin.
Open the NMTR Page at The Online Investor »
|
|||||||||||||||||||||
Open the NMTR Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 84th percentile
(ranked higher than approx. 84% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.